首页> 外文期刊>Urology >Robotic-assisted radical cystectomy with extracorporeal urinary diversion for urothelial carcinoma of the bladder: Analysis of complications and oncologic outcomes in 175 patients with a median follow-up of 3 years
【24h】

Robotic-assisted radical cystectomy with extracorporeal urinary diversion for urothelial carcinoma of the bladder: Analysis of complications and oncologic outcomes in 175 patients with a median follow-up of 3 years

机译:机器人辅助自由基膀胱切除术与膀胱尿路上皮癌的体外尿液转移:175例中位随访3年患者的并发症和肿瘤成果分析

获取原文
获取原文并翻译 | 示例
           

摘要

Objective To report oncologic outcomes and complications after robotic-assisted radical cystectomy (RARC). Materials and Methods From March 2004 to August 2011, 175 consecutive patients underwent RARC with extracorporeal urinary diversion at our institution by a single surgeon. The study design was prospective. Perioperative parameters and postoperative complications were prospectively collected using the modified Clavien system. Recurrence-free survival and cancer-specific survival curves were generated using the Kaplan-Meier method. Results A total of 145 men and 30 women with a median age of 73 years and a median body mass index of 27 kg/m2 underwent RARC. Four patients (2.3%) required conversion to open surgery because of difficulty to progress. One hundred nine patients (62%) underwent a transcutaneous ileal conduit, 40 patients (23%) an orthotopic neobladder, and 26 (15%) a continent cutaneous conduit. The median operating time was 360 minutes (interquartile range [IQR]: 300-420). The median estimated blood loss was 400 mL (IQR: 250-612), with a transfusion rate of 17.0%. The median postoperative length of stay was 7.0 days (IQR: 5.2-10). Early (30 days) and late surgery-related complications (30-90 days) occurred in 74 (42%) and 59 (34%) patients, respectively. The perioperative mortality rate was 2.8%. The positive soft tissue surgical margins rate was 5%. The median number of lymph nodes removed was 19 (IQR: 12-28). The median follow-up was 37 months (IQR: 21.5-53.5). Actuarial recurrence-free survival and cancer-specific survival at 2, 3, and 5 years after RARC were 67%, 63%, 63% and 73%, 68%, 66%, respectively. Conclusion RARC achieved mid-term oncologic efficacy. Moreover, the complication rates were comparable with open radical cystectomy series.
机译:目的报告机器人辅助自由基膀胱切除术(RARC)后的肿瘤蛋白结果和并发症。 2004年3月至2011年8月的材料和方法,连续175名患者接受了RARC的攻击,通过单一外科医生在我们的机构进行了体外尿转水。研究设计是前瞻性的。使用改性的Clavien系统预先收集围手术期参数和术后并发症。使用Kaplan-Meier方法产生无复发的存活和癌症特异性生存曲线。结果共有145名男子和30名女性,中位年龄为73岁,中位体重指数为27公斤/平方米的RARC。四名患者(2.3%)要求转换为开放手术,因为难以进展。一百九名患者(62%)经过经皮髂管,40名患者(23%),标准素新细胞,26(15%)南瓜沟槽。中位运行时间为360分钟(句子范围[IQR]:300-420)。中位数估计失血为400毫升(IQR:250-612),输血率为17.0%。中位术后逗留时间为7.0天(IQR:5.2-10)。早期(30天)和晚期手术相关的并发症(30-90天)分别发生在74(42%)和59名(34%)患者中发生。围手术期死亡率为2.8%。阳性软组织外科余量率为5%。移除的淋巴结数为19(IQR:12-28)。中位后续时间为37个月(IQR:21.5-53.5)。在RARC术后2,3和5年的Actuarial复发存活和癌症特异性存活率分别为67%,63%,63%和73%,6​​8%,66%。结论RARC获得中期肿瘤疗效。此外,并发症率与开放的自由基膀胱切除术系列相当。

著录项

  • 来源
    《Urology》 |2013年第6期|共7页
  • 作者单位

    Department of Urology and Medical Oncology Weill Medical College Cornell University 525 East;

    Department of Urology and Medical Oncology Weill Medical College Cornell University 525 East;

    Department of Urology and Medical Oncology Weill Medical College Cornell University 525 East;

    Department of Urology and Medical Oncology Weill Medical College Cornell University 525 East;

    Department of Urology and Medical Oncology Weill Medical College Cornell University 525 East;

    Department of Urology and Medical Oncology Weill Medical College Cornell University 525 East;

    Department of Pathology Weill Cornell Medical College New York NY United States;

    Department of Urology and Medical Oncology Weill Medical College Cornell University 525 East;

    Department of Urology and Medical Oncology Weill Medical College Cornell University 525 East;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 泌尿科学(泌尿生殖系疾病);
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号